

# Sahil Khanna

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6041921/publications.pdf>

Version: 2024-02-01

204  
papers

6,186  
citations

66343

42  
h-index

82547

72  
g-index

206  
all docs

206  
docs citations

206  
times ranked

6261  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Epidemiology of Community-Acquired Clostridium difficile Infection: A Population-Based Study. American Journal of Gastroenterology, 2012, 107, 89-95.	0.4	518
2	A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection. Journal of Infectious Diseases, 2016, 214, 173-181.	4.0	277
3	Systematic review: colitis associated with anti-CTLA-4 therapy. Alimentary Pharmacology and Therapeutics, 2015, 42, 406-417.	3.7	227
4	A Clinician's Primer on the Role of the Microbiome in Human Health and Disease. Mayo Clinic Proceedings, 2014, 89, 107-114.	3.0	187
5	The Epidemiology of Clostridium difficile Infection in Children: A Population-Based Study. Clinical Infectious Diseases, 2013, 56, 1401-1406.	5.8	182
6	Community-acquired Clostridium difficile infection: an increasing public health threat. Infection and Drug Resistance, 2014, 7, 63.	2.7	169
7	The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Review of Gastroenterology and Hepatology, 2010, 4, 409-416.	3.0	142
8	Low Cure Rates in Controlled Trials of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2019, 68, 1351-1358.	5.8	137
9	Clostridioides difficile uses amino acids associated with gut microbial dysbiosis in a subset of patients with diarrhea. Science Translational Medicine, 2018, 10, .	12.4	128
10	Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection. JAMA Internal Medicine, 2017, 177, 784.	5.1	120
11	Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease. Microbiome, 2017, 5, 55.	11.1	118
12	Clostridium difficile Infection: New Insights Into Management. Mayo Clinic Proceedings, 2012, 87, 1106-1117.	3.0	117
13	Fecal Microbiota Transplantation. JAMA - Journal of the American Medical Association, 2017, 318, 102.	7.4	115
14	Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry. Gastroenterology, 2021, 160, 183-192.e3.	1.3	113
15	Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection Reduces Recurrent Urinary Tract Infection Frequency. Clinical Infectious Diseases, 2017, 65, 1745-1747.	5.8	110
16	Management of Clostridium difficile Infection in Inflammatory Bowel Disease: Expert Review from the Clinical Practice Updates Committee of the AGA Institute. Clinical Gastroenterology and Hepatology, 2017, 15, 166-174.	4.4	109
17	2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patients. World Journal of Emergency Surgery, 2019, 14, 8.	5.0	102
18	Fecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: A multicenter experience. American Journal of Transplantation, 2019, 19, 501-511.	4.7	101

#	ARTICLE	IF	CITATIONS
19	The Epidemiology of Microscopic Colitis in Olmsted County From 2002 to 2010: A Population-Based Study. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 838-842.	4.4	98
20	Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660â€”A Microbiota-Based Drug for the Prevention of Recurrent <i>Clostridium difficile</i> Infection. <i>Clinical Infectious Diseases</i> , 2018, 67, 1198-1204.	5.8	96
21	SER-109, an Investigational Microbiome Drug to Reduce Recurrence After <i>Clostridioides difficile</i> Infection: Lessons Learned From a Phase 2 Trial. <i>Clinical Infectious Diseases</i> , 2021, 72, 2132-2140.	5.8	96
22	Prevalence and Mortality of COVID-19 Patients With Gastrointestinal Symptoms: A Systematic Review and Meta-analysis. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1632-1648.	3.0	95
23	Gut microbiome predictors of treatment response and recurrence in primary <i>Clostridium difficile</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 715-727.	3.7	94
24	Efficacy and safety of ridinilazole compared with vancomycin for the treatment of <i>Clostridium difficile</i> infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 735-744.	9.1	91
25	High risk of postinfectious irritable bowel syndrome in patients with <i>Clostridium difficile</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 576-582.	3.7	89
26	Efficacy of Fecal Microbiota Transplantation for <i>Clostridium difficile</i> Infection in Children. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 612-619.e1.	4.4	81
27	WSES guidelines for management of <i>Clostridium difficile</i> infection in surgical patients. <i>World Journal of Emergency Surgery</i> , 2015, 10, 38.	5.0	78
28	Outcomes in community-acquired <i>Clostridium difficile</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 613-618.	3.7	71
29	<i>Clostridium difficile</i> Infection in Patients With Chronic Kidney Disease. <i>Mayo Clinic Proceedings</i> , 2012, 87, 1046-1053.	3.0	70
30	Faecal microbiota transplantation for eradicating carriage of multidrug-resistant organisms: a systematic review. <i>Clinical Microbiology and Infection</i> , 2019, 25, 958-963.	6.0	66
31	Outcomes of Patients With Microscopic Colitis Treated With Corticosteroids: A Population-Based Study. <i>American Journal of Gastroenterology</i> , 2013, 108, 256-259.	0.4	62
32	Gastric Acid Suppression and Outcomes in <i>Clostridium difficile</i> Infection: A Population-Based Study. <i>Mayo Clinic Proceedings</i> , 2012, 87, 636-642.	3.0	60
33	Clinical Factors Associated With Development of Severe-Complicated <i>Clostridium difficile</i> Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1466-1471.	4.4	60
34	Long-term Safety of Fecal Microbiota Transplantation for Recurrent <i>Clostridioides difficile</i> Infection. <i>Gastroenterology</i> , 2021, 160, 1961-1969.e3.	1.3	59
35	Surotomycin versus vancomycin in adults with <i>Clostridium difficile</i> infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3462-3470.	3.0	57
36	Safety and Efficacy of Fecal Microbiota Transplant for Recurrent <i>Clostridium difficile</i> Infection in Patients With Cancer Treated With Cytotoxic Chemotherapy: A Single-Institution Retrospective Case Series. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1617-1624.	3.0	53

#	ARTICLE	IF	CITATIONS
37	Therapies to modulate gut microbiota: Past, present and future. World Journal of Gastroenterology, 2020, 26, 777-788.	3.3	52
38	Low Risk of Primary Clostridium difficile Infection With Tetracyclines: A Systematic Review and Metaanalysis. Clinical Infectious Diseases, 2018, 66, 514-522.	5.8	51
39	Donor Screening Experience for Fecal Microbiota Transplantation in Patients With Recurrent C. difficile Infection. Journal of Clinical Gastroenterology, 2018, 52, 146-150.	2.2	50
40	Microbiota Replacement Therapies: Innovation in Gastrointestinal Care. Clinical Pharmacology and Therapeutics, 2018, 103, 102-111.	4.7	49
41	The Microbiome in Crohn's Disease. Gastroenterology Clinics of North America, 2017, 46, 481-492.	2.2	45
42	Ipilimumab-induced colitis in patients with metastatic melanoma. Melanoma Research, 2015, 25, 321-327.	1.2	44
43	Immunopathogenesis of juvenile dermatomyositis. Muscle and Nerve, 2010, 41, 581-592.	2.2	41
44	Increasing antibiotic resistance in Clostridioides difficile: A systematic review and meta-analysis. Anaerobe, 2019, 58, 35-46.	2.1	41
45	Clostridium difficile infection: management strategies for a difficult disease. Therapeutic Advances in Gastroenterology, 2014, 7, 72-86.	3.2	38
46	Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial. BMC Infectious Diseases, 2022, 22, 245.	2.9	38
47	Epidemiology, outcomes, and predictors of mortality in hospitalized adults with Clostridium difficile infection. Internal and Emergency Medicine, 2016, 11, 657-665.	2.0	37
48	An Evaluation of Repeat Stool Testing for Clostridium difficile Infection by Polymerase Chain Reaction. Journal of Clinical Gastroenterology, 2012, 46, 846-849.	2.2	35
49	Outcomes With Fidaxomicin Therapy in Clostridium difficile Infection. Journal of Clinical Gastroenterology, 2018, 52, 151-154.	2.2	35
50	Poor outcomes after Clostridium difficile infection in IBD. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 307-308.	17.8	34
51	Extraintestinal Clostridium difficile Infections: A Single-Center Experience. Mayo Clinic Proceedings, 2014, 89, 1525-1536.	3.0	34
52	Systematic review with meta-analysis: the impact of Clostridium difficile infection on the short-term and long-term risks of colectomy in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 1011-1020.	3.7	34
53	Diagnosis and Treatment of Clostridium difficile Infection. JAMA - Journal of the American Medical Association, 2018, 320, 1031.	7.4	31
54	Efficacy of Fecal Microbiota Transplantation for Recurrent C. Difficile Infection in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2020, 26, 1415-1420.	1.9	31

#	ARTICLE	IF	CITATIONS
55	Gut microbiome and <i>Clostridioides difficile</i> infection: a closer look at the microscopic interface. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482199473.	3.2	31
56	Update on Treatment of <i>Clostridioides difficile</i> Infection. <i>Mayo Clinic Proceedings</i> , 2020, 95, 758-769.	3.0	31
57	Clinical implications of antibiotic impact on gastrointestinal microbiota and <i>Clostridium difficile</i> infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1145-1152.	3.0	30
58	RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients' Microbiomes in a Phase 1 Study for Recurrent <i>Clostridioides difficile</i> Infections. <i>Clinical Infectious Diseases</i> , 2021, 73, e1613-e1620.	5.8	27
59	Fecal Microbiota Transplantation for Recurrent <i>Clostridioides difficile</i> infection: The COVID-19 Era. <i>American Journal of Gastroenterology</i> , 2020, 115, 971-974.	0.4	27
60	Clinical predictors of recurrent <i>Clostridium difficile</i> infection in outpatients. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 518-522.	3.7	26
61	The Impact of <i>Clostridium difficile</i> Infection on Mortality in Patients With Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 127-133.	2.2	26
62	Differential coupling of KLF10 to Sin3-HDAC and PCAF regulates the inducibility of the FOXP3 gene. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2014, 307, R608-R620.	1.8	25
63	New-Onset Microscopic Colitis in an Ulcerative Colitis Patient After Fecal Microbiota Transplantation. <i>American Journal of Gastroenterology</i> , 2016, 111, 751-752.	0.4	25
64	Effect of Neutropenic Diet on Infection Rates in Cancer Patients With Neutropenia. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 270-274.	1.3	25
65	Fecal Microbiota Transplantation Is Safe and Effective in Patients With <i>Clostridioides difficile</i> Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1627-1634.	4.4	24
66	The interplay of SARS-CoV-2 and <i>Clostridioides difficile</i> infection. <i>Future Microbiology</i> , 2021, 16, 439-443.	2.0	24
67	Non- <i>Clostridium difficile</i> Bacterial Infections Are Rare in Patients With Flares of Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 528-533.	4.4	23
68	Management of <i>Clostridioides difficile</i> infection in patients with inflammatory bowel disease. <i>Intestinal Research</i> , 2021, 19, 265-274.	2.6	23
69	Trends in the Incidence and Outcomes of Hospitalized Cancer Patients With <i>Clostridium difficile</i> Infection: A Nationwide Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 466-472.	4.9	22
70	Predictors of failure after fecal microbiota transplantation for recurrent <i>Clostridioides difficile</i> infection: a systematic review and meta-analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1383-1392.	2.9	22
71	Repeat <i>Clostridium difficile</i> Testing. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 2422.	7.4	21
72	The incidence and outcomes from <i>Clostridium difficile</i> infection in hospitalized adults with inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1240-1247.	1.5	20

#	ARTICLE	IF	CITATIONS
73	Current and future trends in clostridioides (clostridium) difficile infection management. Anaerobe, 2019, 58, 95-102.	2.1	20
74	Outcomes in Patients with SARS-CoV-2 and Clostridioides difficile Coinfection. Infection and Drug Resistance, 2021, Volume 14, 1645-1648.	2.7	20
75	The Epidemiology of Microscopic Colitis in Olmsted County, Minnesota: Population-Based Study From 2011 to 2019. Clinical Gastroenterology and Hepatology, 2022, 20, 1085-1094.	4.4	19
76	"Community-Acquired Clostridium difficile Infection: An Emerging Entity". Clinical Infectious Diseases, 2012, 55, 1741-1742.	5.8	18
77	Acute Kidney Injury is an Independent Marker of Severity in Clostridium difficile Infection. Journal of Clinical Gastroenterology, 2013, 47, 481-484.	2.2	18
78	Management of Clostridioides difficile colitis: insights for the gastroenterologist. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481984765.	3.2	18
79	Fecal Microbiota Transplantation: Tales of Caution. Clinical Infectious Diseases, 2021, 72, e881-e882.	5.8	18
80	Screening for Clostridium difficile colonization on admission to a hematopoietic stem cell transplant unit may reduce hospital-acquired C difficile infection. American Journal of Infection Control, 2018, 46, 459-461.	2.3	18
81	Predictors and Management of Failed Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. Journal of Clinical Gastroenterology, 2021, 55, 542-547.	2.2	18
82	Experience and Outcomes at a Specialized Clostridium difficile Clinical Practice. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2017, 1, 49-56.	2.4	17
83	Medication use and microscopic colitis: a multicentre retrospective cohort study. Alimentary Pharmacology and Therapeutics, 2021, 53, 1209-1215.	3.7	17
84	Colon Surgery Risk With Corticosteroids Versus Immunomodulators or Biologics in Inflammatory Bowel Disease Patients With Clostridium difficile Infection. Inflammatory Bowel Diseases, 2019, 25, 610-619.	1.9	15
85	Fecal microbiota transplantation for treatment of patients with recurrent Clostridioides difficile infection. Expert Review of Anti-Infective Therapy, 2020, 18, 669-676.	4.4	15
86	Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection. Digestive Diseases and Sciences, 2022, 67, 2763-2770.	2.3	15
87	Acute kidney injury impact on inpatient mortality in Clostridium difficile infection: A national propensity-matched study. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1227-1233.	2.8	14
88	Gut microbiome and checkpoint inhibitor colitis. Intestinal Research, 2021, 19, 360-364.	2.6	14
89	Outcomes in children with Clostridium difficile infection: results from a nationwide survey. Gastroenterology Report, 2016, 4, e007.	1.3	13
90	Avian antibodies (IgY) targeting spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inhibit receptor binding and viral replication. PLoS ONE, 2021, 16, e0252399.	2.5	13

#	ARTICLE	IF	CITATIONS
91	The interplay of <i>Clostridioides difficile</i> infection and inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110202.	3.2	13
92	Appendectomy Is Not Associated With Adverse Outcomes in <i>Clostridium difficile</i> Infection: A Population-Based Study. American Journal of Gastroenterology, 2013, 108, 626-627.	0.4	12
93	Efficacy of oral vancomycin prophylaxis for prevention of <i>Clostridioides difficile</i> infection: a systematic review and meta-analysis. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482199404.	3.2	12
94	My Treatment Approach to <i>Clostridioides difficile</i> Infection. Mayo Clinic Proceedings, 2021, 96, 2192-2204.	3.0	12
95	Budesonide Maintenance in Microscopic Colitis: Clinical Outcomes and Safety Profile From a Population-Based Study. American Journal of Gastroenterology, 2022, 117, 1311-1315.	0.4	12
96	The Integrative Human microbiome project: a mile stone in the understanding of the gut microbiome. Expert Review of Gastroenterology and Hepatology, 2020, 14, 639-642.	3.0	11
97	Composition, diversity and potential utility of intervention-naïve pancreatic cancer intratumoral microbiome signature profiling via endoscopic ultrasound. Gut, 2022, 71, 441-443.	12.1	11
98	Fecal Microbiota Transplantation for Recurrent <i>C difficile</i> Infection During the COVID-19 Pandemic. Mayo Clinic Proceedings, 2021, 96, 1418-1425.	3.0	11
99	Gut microbiota: a target for intervention in obesity. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1169-1179.	3.0	11
100	Epstein-Barr virus-associated nephrotic syndrome. CKJ: Clinical Kidney Journal, 2012, 5, 50-52.	2.9	10
101	Outcomes from Rectal Vancomycin Therapy in Patients With <i>Clostridium difficile</i> Infection. American Journal of Gastroenterology, 2014, 109, 924-925.	0.4	10
102	<i>Clostridium difficile</i> infection after restorative proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis. Colorectal Disease, 2016, 18, O154-7.	1.4	10
103	Safety of fecal microbiota transplantation for <i>Clostridioides difficile</i> infection focusing on pathobionts and SARS-CoV-2. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110096.	3.2	10
104	Microbiota restoration for recurrent <i>Clostridioides difficile</i> : Getting one step closer every day!. Journal of Internal Medicine, 2021, 290, 294-309.	6.0	10
105	Ipilimumab-associated colitis or refractory <i>Clostridium difficile</i> infection?. BMJ Case Reports, 2015, 2015, bcr2015211160.	0.5	10
106	Efficacy and Safety of RBX2660 for the Prevention of Recurrent <i>Clostridium difficile</i> Infection: Results. of the PUNCH CD 2 Trial. Open Forum Infectious Diseases, 2016, 3, .	0.9	9
107	Gut-Brain Axis and its Neuro-Psychiatric Effects: A Narrative Review. Cureus, 2020, 12, e11131.	0.5	9
108	Increasing Numbers and Reported Adverse Events in Patients with Lung Cancer Undergoing Inpatient Lung Biopsies: A Population-Based Analysis. Lung, 2019, 197, 593-599.	3.3	8



#	ARTICLE	IF	CITATIONS
109	Durability of Response to Fecal Microbiota Transplantation After Exposure to Risk Factors for Recurrence in Patients With <i>Clostridioides difficile</i> Infection. <i>Clinical Infectious Diseases</i> , 2021, 73, e1706-e1712.	5.8	8
110	Immune response against <i>Clostridioides difficile</i> and translation to therapy. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110148.	3.2	8
111	Statin use and the risk of <i>Clostridium difficile</i> infection: a systematic review with meta-analysis. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 405-416.	2.7	7
112	<i>Clostridium difficile</i> Infection in the Emergency Department. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 350-355.	2.2	7
113	The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of <i>Clostridioides difficile</i> Infection. <i>Diseases of the Colon and Rectum</i> , 2021, 64, 650-668.	1.3	7
114	Systematic Review and Meta-Analysis: Efficacy of Vancomycin Taper and Pulse Regimens in <i>Clostridioides difficile</i> Infection. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 577-583.	4.4	7
115	<i>Clostridium difficile</i> infection: Updates in management. <i>Indian Journal of Gastroenterology</i> , 2017, 36, 3-10.	1.4	6
116	Microbiota replacement for <i>Clostridium difficile</i> by capsule is as effective as via colonoscopy. <i>Journal of Thoracic Disease</i> , 2018, 10, S1081-S1083.	1.4	6
117	Novel risk factors and outcomes in inflammatory bowel disease patients with <i>Clostridioides difficile</i> infection. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482199779.	3.2	6
118	Stool banking for fecal microbiota transplantation: ready for prime time?. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 110-112.	1.5	6
119	RBX2660 is Safe, Superior to Antibiotic-Treated Controls for Preventing Recurrent <i>Clostridium difficile</i> , and May Rehabilitate Patient Microbiomes: Open Label Trial Results. <i>Open Forum Infectious Diseases</i> , 2017, 4, S535-S535.	0.9	5
120	Presence of immune deficiency increases the risk of hospitalization in patients with norovirus infection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 90, 300-306.	1.8	5
121	Trends in Outcomes of Patients With Metastatic Cancer Undergoing Intubation and Mechanical Ventilation: Results of the National Hospital Discharge Survey. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 286-292.	4.9	5
122	37 FECAL MICROBIOTA TRANSPLANTATION IS HIGHLY EFFECTIVE IN REAL-WORLD PRACTICE: INITIAL RESULTS FROM THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION FECAL MICROBIOTA TRANSPLANTATION NATIONAL REGISTRY. <i>Gastroenterology</i> , 2020, 158, S-14-S-15.	1.3	5
123	Increased reporting but decreased mortality associated with adverse events in patients undergoing lung cancer surgery: Competing forces in an era of heightened focus on care quality?. <i>PLoS ONE</i> , 2020, 15, e0231258.	2.5	5
124	Sa611 INTERIM ANALYSIS OF A PHASE 3 OPEN-LABEL STUDY INDICATES SAFETY AND EFFICACY OF RBX2660, AN INVESTIGATIONAL LIVE BIOTHERAPEUTIC, IN A "REAL-WORLD" POPULATION OF PATIENTS WITH RECURRENT <i>CLOSTRIDIoidES DIFFICILE</i> INFECTION. <i>Gastroenterology</i> , 2021, 160, S-573.	1.3	5
125	Palmar-plantar erythrodysesthesia. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015212434.	0.5	4
126	Outcomes in Patients with Recurrent <i>Clostridium Difficile</i> Infection Treated with Vancomycin Taper. <i>Gastroenterology</i> , 2017, 152, S348.	1.3	4



#	ARTICLE	IF	CITATIONS
127	In Search of the (Clostridium difficile) Holy Grail. Clinical Infectious Diseases, 2019, 70, 1094-1095.	5.8	4
128	Microscopic Colitis and Risk of Colon Adenomas: A Multicenter Retrospective Cohort Study. Clinical Gastroenterology and Hepatology, 2022, 20, e902-e904.	4.4	4
129	Fecal microbiota transplant via colonoscopy may be preferred due to intraprocedure findings. Intestinal Research, 2019, 17, 434-437.	2.6	4
130	Esophageal vascular ectasia. Endoscopy, 2011, 43, E281-E281.	1.8	3
131	Mo1656 Outcomes of Fidaxomicin Treatment of Clostridium difficile Infection. Gastroenterology, 2016, 150, S744.	1.3	3
132	Alterations in Microbial Diversity are Associated with Treatment Success with RBX2660, A Microbiota-Based Drug for the Prevention of Recurrent Clostridium Difficile Infection: Results from Punch CD 2, A Randomized Doubleblind Placebo-Controlled Trial. Gastroenterology, 2017, 152, S46-S47.	1.3	3
133	Do tetracyclines have the potential to reduce the risk of Clostridium difficile infection?. Expert Review of Anti-Infective Therapy, 2018, 16, 183-185.	4.4	2
134	Mo1954 " Fecal Microbiota Transplantation is Safe and Effective for the Treatment of Clostridium Difficile Infection in Patients with Liver Cirrhosis. Gastroenterology, 2019, 156, S-898-S-899.	1.3	2
135	Tu1880 " Durable Freedom from Clostridium Difficile Infection Recurrence and Microbiome Restoration During Six-Month Follow-Up For a Phase 1 Clinical Trial of Rbx7455?An Investigational Room Temperature-Stable, Oral Microbiotabased Therapeutic. Gastroenterology, 2019, 156, S-1158.	1.3	2
136	Mo1952 " Efficacy of Oral Vancomycin Prophylaxis for Prevention of Clostridioides Difficile Infection: A Systematic Review and Meta-Analysis. Gastroenterology, 2019, 156, S-897-S-898.	1.3	2
137	Distinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360, 2019, 1, .	1.1	2
138	Tu1793 BILE ACID MALABSORPTION AND OUTCOMES AFTER TREATMENT WITH COLESEVELAM IN MICROSCOPIC COLITIS. Gastroenterology, 2020, 158, S-1163-S-1164.	1.3	2
139	Postinfection Irritable Bowel Syndrome Following Clostridioides difficile Infection. Journal of Clinical Gastroenterology, 2021, Publish Ahead of Print, .	2.2	2
140	Body Mass Index Changes After Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection. American Journal of Gastroenterology, 2016, 111, S103.	0.4	2
141	Outcomes of Clostridium difficile Infection in Patients With Obesity: A Nationwide Analysis. American Journal of Gastroenterology, 2018, 113, S121-S122.	0.4	2
142	Transitions of care in Clostridioides difficile infection: a need of the hour. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210786.	3.2	2
143	Letter: anti-CTLA-4-associated colitis and inflammatory bowel disease pathogenesis - authors' reply. Alimentary Pharmacology and Therapeutics, 2015, 42, 1032-1033.	3.7	1
144	Hemolyzed blood as a clue to the diagnosis of abdominal pain. Internal and Emergency Medicine, 2016, 11, 609-610.	2.0	1

#	ARTICLE	IF	CITATIONS
145	Microbiome Profile is Distinct in Patients with Successful Response to Microbiota-Based Drug RBX2660 Relative to Placebo Responders. <i>Open Forum Infectious Diseases</i> , 2017, 4, S538-S538.	0.9	1
146	Successful Response to Microbiota-Based Drug RBX2660 in Patients with Recurrent Clostridium Difficile Infection is Associated with More Pronounced Alterations in Microbiome Profile. <i>Open Forum Infectious Diseases</i> , 2017, 4, S387-S387.	0.9	1
147	624 “ Comparison of Two Open-Label Trials Demonstrates Similar 6-Month Outcomes for Rbx2660 and Rbx7455” Investigational Microbiota Restoration Therapeutics Administered by Enema Or Oral Capsules for Preventing Recurrent Clostridium Difficile Infections. <i>Gastroenterology</i> , 2019, 156, S-130-S-131.	1.3	1
148	Treatment of Recurrent Clostridium difficile Infection”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 513.	7.4	1
149	Reply to Khoruts and Sadowsky. <i>Clinical Infectious Diseases</i> , 2019, 69, 2233-2234.	5.8	1
150	201 “Efficacy of Fecal Microbiota Transplantation for Acute Graft Versus Host Disease in the Gut: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2019, 114, S123-S123.	0.4	1
151	Mo1951 REPORTING OF RANDOMIZED CONTROLLED TRIAL METHODOLOGICAL CHARACTERISTICS OF FECAL MICROBIOTA TRANSPLANTATION (FMT) FOR RECURRENT CLOSTRIDIODES DIFFICILE INFECTION (RCDI). <i>Gastroenterology</i> , 2020, 158, S-990-S-991.	1.3	1
152	844 MEDICATION USE AND MICROSCOPIC COLITIS: A MULTICENTER RETROSPECTIVE COHORT STUDY. <i>Gastroenterology</i> , 2020, 158, S-170.	1.3	1
153	Mo1950 HETEROGENEITY OF RANDOMIZED CONTROLLED TRIALS OF FECAL MICROBIOTA TRANSPLANTATION (FMT) IN RECURRENT CLOSTRIDIODES DIFFICILE INFECTION: A SYSTEMATIC REVIEW. <i>Gastroenterology</i> , 2020, 158, S-990.	1.3	1
154	Incidence of Clostridioides difficile infection in peripartum women: a retrospective cohort study. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482094262.	3.2	1
155	Tu1797 MANAGEMENT OF PATIENTS WITH HISTOLOGICALLY PROVEN CHECKPOINT-INHIBITOR COLITIS. <i>Gastroenterology</i> , 2020, 158, S-1165.	1.3	1
156	Gut Involvement by COVID-19. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2309-2311.	3.0	1
157	Defending against a difficult clostridioides with a vaccine. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 157-158.	9.1	1
158	Advances in Clostridioides difficile therapeutics. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1067-1070.	4.4	1
159	74-Year-Old Woman With Chronic Diarrhea. <i>Mayo Clinic Proceedings</i> , 2021, 96, 770-775.	3.0	1
160	Fr249 THE EPIDEMIOLOGY OF MICROSCOPIC COLITIS BETWEEN 2011-2019: AN OLMSTED COUNTY, MINNESOTA POPULATION-BASED STUDY. <i>Gastroenterology</i> , 2021, 160, S-278.	1.3	1
161	In reply”Lack of Marked Association Between Gastrointestinal Symptoms and COVID-19 Mortality: An Updated Meta-analysis Based on Adjusted Effect Estimates. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1680-1681.	3.0	1
162	Efficacy of Fecal Microbiota Transplant in Hematological Cancers Patients with Recurrent Clostridioides Difficile Infection: A Systemic Review and Meta-Analysis. <i>Blood</i> , 2019, 134, 5870-5870.	1.4	1

#	ARTICLE	IF	CITATIONS
163	119 Kinetics of Stool Polymerase Chain Reaction in Clostridioides difficile Infection and Its Utility in Predicting Recurrence. American Journal of Gastroenterology, 2019, 114, S71-S72.	0.4	1
164	Mo1889 CORRELATION OF EARLY INFLIXIMAB LEVELS WITH SHORT TERM OUTCOMES IN STEROID REFRACTORY ULCERATIVE COLITIS: A PILOT STUDY. Gastroenterology, 2020, 158, S-964-S-965.	1.3	1
165	An Important Mimicker. Gastroenterology, 2022, 162, 1840-1843.	1.3	1
166	Clostridioides difficile infection: curbing a difficult menace. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210899.	3.2	1
167	52-Year-Old Woman With Dysphagia. Mayo Clinic Proceedings, 2010, 85, 760-763.	3.0	0
168	1620Extraintestinal Clostridium difficile infections: A Single Center Experience. Open Forum Infectious Diseases, 2014, 1, S433-S433.	0.9	0
169	Adherence to Treatment Guidelines for Incident Clostridium difficile Infection in Critically Ill Adults. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
170	Letter: cytomegalovirus colitis in a patient treated with ipilimumab for metastatic melanoma - authors' reply. Alimentary Pharmacology and Therapeutics, 2016, 43, 176-176.	3.7	0
171	Tetracyclines are Associated with a Reduced Risk of Clostridium difficile Infection: A Systematic Review and Meta-analysis. Open Forum Infectious Diseases, 2017, 4, S384-S384.	0.9	0
172	Testing for Clostridium difficile in Patients With Cancer. Journal of Oncology Practice, 2017, 13, 344-344.	2.5	0
173	Reply to Davido et al. Clinical Infectious Diseases, 2018, 66, 483-485.	5.8	0
174	The Role of Anchoring in Working Up Diarrhea: A Practical Teaching Case. Gastroenterology, 2018, 154, 498-499.	1.3	0
175	1950. Prevention of Recurrent Clostridium difficile at Six Months Following Treatment With Microbiota-Based Therapy RBX2660: Durability Results From a Phase 2 Open-Label Study. Open Forum Infectious Diseases, 2018, 5, S562-S563.	0.9	0
176	Mo1923 " Long-Term Safety of Fecal Microbiota Transplantation in the Treatment of Recurrent Clostridioides Difficile Infection. Gastroenterology, 2019, 156, S-888.	1.3	0
177	Trends in the Incidence and Outcomes of Clostridioides difficile infection in Hematologic Cancers: A Nationwide Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S357-S358.	0.4	0
178	Mo1939 " Peripartum Clostridioides Difficile Infection and Its Effect on Pregnancy and Neonatal Outcomes: A Retrospective Cohort Study. Gastroenterology, 2019, 156, S-892-S-893.	1.3	0
179	Mo1960 " Corticosteroids and Adverse Outcomes in Inflammatory Bowel Disease Patients with Clostridium Difficile Infections: A Systematic Review and Meta-Analysis. Gastroenterology, 2019, 156, S-901-S-902.	1.3	0
180	2432. Durability Against Antibiotics After Response to Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection. Open Forum Infectious Diseases, 2019, 6, S841-S841.	0.9	0

#	ARTICLE	IF	CITATIONS
181	P1.16-01 Complications Associated with Lung Biopsies in Patients with Lung Cancer: A Population Based Analysis. <i>Journal of Thoracic Oncology</i> , 2019, 14, S585.	1.1	0
182	Reply to Lagier et al. <i>Clinical Infectious Diseases</i> , 2020, 70, 2454-2455.	5.8	0
183	Mo1942 OUTCOMES OF CLOSTRIDIODES DIFFICILE INFECTION IN SURGICAL PATIENTS: RESULTS FROM NATIONAL INPATIENT SAMPLE. <i>Gastroenterology</i> , 2020, 158, S-986-S-987.	1.3	0
184	Sa1008 INCIDENCE OF CLOSTRIDIODES DIFFICILE INFECTION FROM 2006-2017: RESULTS FROM THE ROCHESTER EPIDEMIOLOGY PROJECT. <i>Gastroenterology</i> , 2020, 158, S-239-S-240.	1.3	0
185	Mo1794 FECAL MICROBIOTA TRANSPLANTATION FOR C. DIFFICILE INFECTION IN INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. <i>Gastroenterology</i> , 2020, 158, S-923.	1.3	0
186	Response to "Comments on the published systematic review and meta-analysis on the increasing antibiotic resistance in <i>Clostridioides difficile</i> " by Kouhsari et al.. <i>Anaerobe</i> , 2020, 61, 102148.	2.1	0
187	Microbiome-based Therapies for Multidrug-resistant Pathobionts: Getting a Step Closer!. <i>Clinical Infectious Diseases</i> , 2021, 72, 1448-1449.	5.8	0
188	RISK FACTORS FOR OUTCOMES OF PATIENTS WITH HISTOLOGICALLY PROVEN CHECKPOINT-INHIBITOR COLITIS. <i>Gastroenterology</i> , 2021, 160, S49-S50.	1.3	0
189	Neutralization of Fecal Aerosol-Laden SARS CoV-2: Public Health Implications. <i>Mayo Clinic Proceedings</i> , 2021, 96, 818-819.	3.0	0
190	A defined microbiome therapeutic prevents recurrent <i>Clostridioides difficile</i> . <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 255-256.	8.1	0
191	Fr246 THE NATURAL COURSE OF HISTOLOGICAL CHANGES IN MICROSCOPIC COLITIS. <i>Gastroenterology</i> , 2021, 160, S-277.	1.3	0
192	Su305 ENDOSCOPIC ULTRASOUND FOR PANCREAS INTRATUMORAL MICROBIOME SIGNATURE PROFILING: COMPOSITION, DIVERSITY, AND POTENTIAL UTILITY. <i>Gastroenterology</i> , 2021, 160, S-667-S-668.	1.3	0
193	Fr632 EVALUATION OF BODY MASS INDEX AND NEUROPSYCHIATRIC DISEASES IN OFFSPRING BORN TO MOTHERS WITH PERIPARTUM CLOSTRIDIODES DIFFICILE INFECTION. <i>Gastroenterology</i> , 2021, 160, S-384.	1.3	0
194	ID: 3518327 PANCREAS INTRA-TUMORAL MICROBIOME COMPOSITION AND DIVERSITY SIGNATURE PROFILING BY ENDOSCOPIC ULTRASOUND ANATOMIC LOCATION. <i>Gastrointestinal Endoscopy</i> , 2021, 93, AB254.	1.0	0
195	Reply. <i>Gastroenterology</i> , 2021, 161, 1345.	1.3	0
196	Kinetics of polymerase chain reaction positivity in patients with <i>Clostridioides difficile</i> infection. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110504.	3.2	0
197	Safety and Efficacy of Fecal Microbiota Transplantation for Recurrent <i>Clostridium</i> Infection in Patients with Hematologic Malignancies. <i>Blood</i> , 2016, 128, 3599-3599.	1.4	0
198	Risk Factors of <i>Clostridium Difficile</i> Infection in Hematopoietic Stem Cell Transplant Recipients: A Systemic Review and Meta-Analysis. <i>Blood</i> , 2018, 132, 4704-4704.	1.4	0

#	ARTICLE	IF	CITATIONS
199	Trends in the incidence and outcomes of Clostridioides difficile infection in hematological cancers: A nationwide analysis.. Journal of Clinical Oncology, 2019, 37, e18244-e18244.	1.6	0
200	Microscopic Colitis and Risk of Colon Adenomas: A Multicenter Retrospective Cohort Study. American Journal of Gastroenterology, 2019, 114, S72-S72.	0.4	0
201	Inpatient Fecal Microbiota Transplantation for the Treatment of Refractory Severe-Complicated Clostridioides difficile Infection. American Journal of Gastroenterology, 2019, 114, S1557-S1557.	0.4	0
202	Novel Risk Factors and Outcomes in Inflammatory Bowel Disease Patients With Clostridium difficile Infection. American Journal of Gastroenterology, 2019, 114, S441-S442.	0.4	0
203	Clostridial vaccines in the pipeline. Drugs of the Future, 2020, 45, 653.	0.1	0
204	Outcomes of Pediatric Hospital and Community-Associated Clostridioides difficile Infection. American Journal of Gastroenterology, 2020, 115, S68-S68.	0.4	0